Influenza A Infections Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest Approvals by DelveInsight

Influenza A Infections companies are Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart, and others.

LAS VEGAS, NEVADA, UNITED STATES, June 9, 2024 /EINPresswire.com/ -- DelveInsight’s “Influenza A Infections Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Influenza A Infections, historical and forecasted epidemiology as well as the Influenza A Infections market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Influenza A Infections market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Influenza A Infections Market Forecast

Some of the key facts of the Influenza A Infections Market Report:

The Influenza A Infections market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
Key Influenza A Infections Companies: Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart, and others
Key Influenza A Infections Therapies: CD388, SAB-176, M2SR, VIR-2482, mRNA-1010, GSK3206641A, VXA-A1.1, and others
TAMIFLU is a prescription medicine used as prophylaxis to treat the symptoms of Influenza A and B and swine flu (H1N1 Influenza A)
RELENZA is a prescription medicine used as a prophylaxis to treat influenza symptoms. Relenza may be used alone or with other medications
RAPIVAB is a prescription medicine used to treat the symptoms of influenza. Rapivab may be used alone or with other medications
The total vaccinated pool of Influenza A in the United States is approximately 176 million in 2021.
The total Influenza A positive cases in the United States comprised of 42,580 cases in 2021 and are projected to increase during the study period.
In the United States, there were (H1N1)pdm09, H3N2, and subtyping not performed 19, 7,405, and 35,156 cases in 2021.
The total Influenza A market size in the United States is USD 3,623 million in 2021 and is projected to grow during the forecast period (2022-2032).
In 2021, among all the therapy-wise Influenza A market sizes, the highest revenue was generated by FLUZONE (High Dose)/FLUBLOK i.e., ~USD 1164 million while FLUMIST generated the lowest revenue i.e., ~USD 29 million in the US.
Between the prophylaxis market and treatment market, prophylaxis market is expected to capture more share with many potential candidates including CD388, VXA-A1.1, VIR-2482, mRNA-1010, and others present in the emerging pipeline.
The Influenza A Infections market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Influenza A Infections pipeline products will significantly revolutionize the Influenza A Infections market dynamics.

Influenza A Infections Overview

The influenza virus affects the respiratory tract either through direct viral infection or damage from the immune system response. In humans, the respiratory epithelium is the primary site where the hemagglutinin (HA) molecule is effectively cleaved, leading to the generation of infectious virus particles. Virus transmission occurs through contact with aerosols or respiratory fomites from an infected individual. Various mechanisms can impair the lung's ability to perform gas exchange, including airway obstruction, loss of alveolar structure, disruption of lung epithelial integrity due to direct cell killing, and degradation of the extracellular matrix.

In adults, influenza A virus is the predominant viral cause of acute respiratory distress syndrome (ARDS). Risk factors independently associated with ARDS include ages between 36 and 55, pregnancy, and obesity, while protective factors include female sex, influenza vaccination, and infections with Influenza A (H3N2) or Influenza B viruses.

Influenza viruses are classified into four types: A, B, C, and D. Human influenza A and B viruses typically cause seasonal epidemics (commonly known as flu season) almost every winter in the United States. Influenza A viruses are the sole cause of flu pandemics, which are global epidemics of flu disease. Pandemics occur when a new and different influenza A virus infects people and spreads efficiently among them. Influenza C virus infections typically result in mild illness and are not associated with human epidemics. Influenza D viruses primarily affect cattle and are not known to infect or cause illness in humans.

Influenza A Infections Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Influenza A Infections Epidemiology Segmentation:

The Influenza A Infections market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Influenza A Infections
Prevalent Cases of Influenza A Infections by severity
Gender-specific Prevalence of Influenza A Infections
Diagnosed Cases of Episodic and Chronic Influenza A Infections

Download the report to understand which factors are driving Influenza A Infections epidemiology trends @ Influenza A Infections Epidemiology Forecast

Influenza A Infections Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Influenza A Infections market or expected to get launched during the study period. The analysis covers Influenza A Infections market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Influenza A Infections Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Influenza A Infections Key Companies

Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart

Influenza A Infections Therapies

CD388, SAB-176, M2SR, VIR-2482, mRNA-1010, GSK3206641A, VXA-A1.1

Discover more about therapies set to grab major Influenza A Infections market share @ Influenza A Infections Treatment Landscape

Influenza A Infections Market Outlook

Influenza, commonly known as the flu, is a respiratory illness caused by a viral infection and is highly contagious, spreading through respiratory droplets. Most individuals can manage flu symptoms at home using a combination of lifestyle remedies and over-the-counter medication.

In temperate climate regions, such as the US, influenza activity typically peaks during the winter months, leading to annual seasonal epidemics with varying degrees of severity and significant morbidity and mortality. Annual influenza vaccination is recommended for all individuals aged 6 months and older in the US, particularly those at increased risk of influenza-related complications, such as young children and the elderly. Observational studies have shown that influenza vaccination can reduce the risk of severe disease requiring hospitalization, intensive care unit admission, and death.

Antiviral medications play a crucial role in controlling influenza by treating the infection and preventing severe complications, such as bacterial pneumonia. Prompt administration of antiviral drugs can alleviate flu symptoms and shorten the duration of illness by an average of one day. Early treatment is particularly important for high-risk individuals, such as the elderly or those with compromised immune systems. Currently, four antiviral drugs are recommended for treating influenza: TAMIFLU (oseltamivir), RELENZA (zanamivir), RAPIVAB (peramivir), and XOFLUZA (baloxavir marboxil). These drugs work by inhibiting the function of neuraminidase on the virus surface, thereby preventing the release of viral particles from infected cells. They are most effective when taken within 48 hours of symptom onset.

In the past, FLUMADINE (rimantadine) and SYMMETREL (amantadine) were used to treat influenza A infections by disrupting ion channels in the virus wall, inhibiting viral replication. However, due to widespread resistance and limited effectiveness against influenza B, these drugs are no longer recommended for flu treatment in the US.

The influenza A market is expected to undergo changes in the coming years due to increased healthcare spending worldwide. Companies like Sab Biotherapeutics (SAB-176), Flugen (M2SR), Moderna (mRNA-1010), Vir Biotechnology (VIR-2482), Vaxart (VXA-A1.1), and others are advancing clinical development of investigational candidates, which may alter market dynamics in the future.

Scope of the Influenza A Infections Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Influenza A Infections Companies: Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart, and others
Key Influenza A Infections Therapies: CD388, SAB-176, M2SR, VIR-2482, mRNA-1010, GSK3206641A, VXA-A1.1, and others
Influenza A Infections Therapeutic Assessment: Influenza A Infections current marketed and Influenza A Infections emerging therapies
Influenza A Infections Market Dynamics: Influenza A Infections market drivers and Influenza A Infections market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Influenza A Infections Unmet Needs, KOL’s views, Analyst’s views, Influenza A Infections Market Access and Reimbursement

Table of Contents

1. Influenza A Infections Market Report Introduction
2. Executive Summary for Influenza A Infections
3. SWOT analysis of Influenza A Infections
4. Influenza A Infections Patient Share (%) Overview at a Glance
5. Influenza A Infections Market Overview at a Glance
6. Influenza A Infections Disease Background and Overview
7. Influenza A Infections Epidemiology and Patient Population
8. Country-Specific Patient Population of Influenza A Infections
9. Influenza A Infections Current Treatment and Medical Practices
10. Influenza A Infections Unmet Needs
11. Influenza A Infections Emerging Therapies
12. Influenza A Infections Market Outlook
13. Country-Wise Influenza A Infections Market Analysis (2019–2032)
14. Influenza A Infections Market Access and Reimbursement of Therapies
15. Influenza A Infections Market Drivers
16. Influenza A Infections Market Barriers
17. Influenza A Infections Appendix
18. Influenza A Infections Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Influenza A Infections Pipeline

"Influenza A Infections Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Influenza A Infections market. A detailed picture of the Influenza A Infections pipeline landscape is provided, which includes the disease overview and Influenza A Infections treatment guidelines.

Influenza A Infections Epidemiology

DelveInsight's 'Influenza A Infections Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Influenza A Infections epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Kritika Rehani
DelveInsight Business Research LLP
+1 469-945-7679
email us here